PL-001 is under clinical development by Pell Bio-Med Technology and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PL-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PL-001 is under development for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL), large B-cell lymphoma transformed from follicular lymphoma (FL). It is administered through intravenous route. The therapeutic candidate comprises T cells genetically modified to express chimeric antigen receptor (CAR) targeting cells expressing CD19.
Pell Bio-Med Technology overview
Pell Bio-Med Technology (Pell BMT) focuses on development of cell culture technologies and techniques for therapeutic applications. Pell BMT is headquartered in Kaohsiung, Taiwan.
For a complete picture of PL-001’s drug-specific PTSR and LoA scores, buy the report here.